课题基金 / 基金详情

Growth regulatory targets of the Tuberous Sclerosis Complex

Growth regulatory targets of the Tuberous Sclerosis Complex
结节性硬化症复合体的生长调节目标
批准号:
7131928
负责人:
Bruce Alexander Edgar
金额:
$38.93万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-09-10 至 2011-05-31

项目摘要

项目成果

Bruce Alexander Edgar的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Tuberous sclerosis (TS) is an autosomal dominant disease that causes widespread benign tumors in many tissues including the brain, lung, kidney, skin, eyes, and teeth. Although TS is rarely fatal it causes debilitating complications such as seizures, mental retardation, and heart obstruction. Tumors can arise throughout life, and in severe cases cause kidney or heart failure in adults. The disease is highly prevalent, affecting approximately 1/6000 individuals, or about 50,000 in the US population. There is no cure. Most cases of TS are caused by loss of function in one of two genes, TSC1 or TSC2, which encode a protein complex. The TSC1/2 complex mediates many of its effects by inhibiting the activity of Rheb, an essential activator of the Target-Of-Rapamycin (TOR) kinase, which is a central regulator of cell growth. TOR controls diverse metabolic processes required for cell growth including protein synthesis, nutrient import, autophagy, and transcription. It has two well-characterized targets in humans, S6K and 4EBP, but genetic analysis in Drosophila and mice indicate that these targets cannot account for the striking overgrowth phenotypes that occur in tuberous sclerosis. Moreover, it is has not been demonstrated that all of the downstream effects of TSC mutation are mediated via Rheb and/or TOR. Hence the identification and characterization of additional effectors of TSC1/2 complex is required to advance our understanding of the molecular and cellular basis of this disease. This project will use genetic and proteomic approaches in Drosophila and human cells to: 1) Evaluate the hypothesis that the TSC1/2 complex mediates all of its effects via Rheb and TOR, and; 2) Identify and characterize new gene products required for TSC1/2 and Rheb function. Such genes are expected to be effectors of deregulated cell growth in tuberous sclerosis, and as such constitute potential targets for diagnosis and treatment of the disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of cell growth and proliferation
  • 批准号:
    10395545
  • 项目类别:
  • 资助金额:
    $75.26万
  • 财政年份:
    2021
  • 负责人:
    Bruce Alexander Edgar
  • 依托单位:
Regulation of cell growth and proliferation
  • 批准号:
    10615619
  • 项目类别:
  • 资助金额:
    $75.26万
  • 财政年份:
    2021
  • 负责人:
    Bruce Alexander Edgar
  • 依托单位:
Sex steroid signaling and adaptive growth of the intestine
  • 批准号:
    10579238
  • 项目类别:
  • 资助金额:
    $47.27万
  • 财政年份:
    2021
  • 负责人:
    Bruce Alexander Edgar
  • 依托单位:
Sex steroid signaling and adaptive growth of the intestine
  • 批准号:
    10378067
  • 项目类别:
  • 资助金额:
    $47.27万
  • 财政年份:
    2021
  • 负责人:
    Bruce Alexander Edgar
  • 依托单位:
国内基金
海外基金
精神分裂症脑网络异常的影像遗传学研究
  • 批准号:
    81000582
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2010
  • 负责人:
    刘冰
  • 依托单位:
孤独症全基因组关联第二阶段研究
  • 批准号:
    81071110
  • 项目类别:
    面上项目
  • 资助金额:
    32.0万元
  • 批准年份:
    2010
  • 负责人:
    王力芳
  • 依托单位:
孤独症与突触发育相关候选基因的关联研究
  • 批准号:
    30870897
  • 项目类别:
    面上项目
  • 资助金额:
    50.0万元
  • 批准年份:
    2008
  • 负责人:
    张岱
  • 依托单位:
用dsDNA微阵列筛选NF-κB DNA靶点及靶基因
  • 批准号:
    60871014
  • 项目类别:
    面上项目
  • 资助金额:
    35.0万元
  • 批准年份:
    2008
  • 负责人:
    王进科
  • 依托单位: